Biogen Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
/ 
Frequently asked questions
To buy Biogen Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Biogen Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Biogen Inc. is BIIB:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Biogen Inc. has its primary listing on NASDAQ. You can trade Biogen Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Biogen Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Biogen Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Biogen Inc..